Newron presents encouraging interim results for evenamide in patients with Treatment-Resistant Schizophrenia (TRS) at the 33rd CINP Hybrid World Congress of Neuropsychopharmacology
 

Interim results show improved symptoms of psychosis in patients with chronic TRS

Study 014 represents first international trial of a New Chemical Entity (NCE) antipsychotic as an add-on in TRS, with treatment implications for TRS patients

Newron to host an investor, analyst and media conference call today at 3 pm CET/ 9 am ET
 

Milan, Italy, June 7, 2022, 7 am CET – Newron Pharmaceuticals S.p.A. (“Newron”) (SIX: NWRN, XETRA: NP5), a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system (CNS), today announced encouraging interim results from the first 100 patients in its world-first, international, six-week, open-label, randomized, rater-blinded, multi-centre study of evenamide as an add-on to an antipsychotic in patients with moderate to severe treatment-resistant schizophrenia (TRS) who were not responding to current antipsychotic medication.

The results presented at the 33^rd Collegium Internationale Neuro-Psychopharmacologicum (CINP) Hybrid World Congress of Neuropsychopharmacology, in Taipei, Taiwan, show that the addition of evenamide (7.5/15/30mg bid) improved symptoms of psychosis in patients with chronic TRS, reflected by an approximately 12% reduction in the PANSS score, CGI-S improvement of 0.7, and CGI-C ratings indicating 77% of patients responded to the treatment. The first 100 patients were mostly treated with the 7.5 and 15 mg bid doses, as patients were initially randomized to treatment with these doses; an Independent Safety Monitoring Board reviewed the safety data from the first 50 patients completing the trial prior to allowing randomization to the 30 mg bid dose.

Ravi Anand, M.D., Newron’s Chief Medical Officer, stated: “We are excited to present the interim results of this study, which demonstrate the potential of evenamide as an add-on therapy to antipsychotics in patients with treatment resistant schizophrenia. The data presented today confirm evenamide’s potential to improve symptoms of psychosis in patients who, despite treatment with various antipsychotics, continue to experience severe symptoms of psychosis and functional disabilities. These patients represent about one third of the overall schizophrenia population and thus a significant unmet medical need. Evenamide acts through selective attenuation of an abnormal release of glutamate and synergizing with the background antipsychotic activity. The outcome of this study may change the treatment of future TRS patients when confirmed in a larger, placebo-controlled study.”

Newron expects to initiate a potentially pivotal, multinational, randomized, placebo-controlled study in patients with treatment resistant schizophrenia in the first quarter of 2023, as part of its ongoing Phase II/III development plan for evenamide.
 

Study 014 design
This six-week, randomized, rater-blinded study is being conducted at multiple sites in three countries. The study will include approximately 180 patients with TRS on a stable, therapeutic dose of a single antipsychotic other than clozapine. The primary objective of the study is to evaluate the safety and tolerability of evenamide given orally at three fixed doses (7.5, 15 and 30 mg bid). The assessment of preliminary efficacy, based on changes from baseline in the Positive and Negative Syndrome Scale (PANSS), Clinical Global Impression - Change from baseline (CGI-C), Severity of illness (CGI-S), and Strauss-Carpenter Level of Functioning (LOF) scale, is a secondary objective.

Patients were moderately to severely ill (CGI-S of 4 to 6), with a baseline PANSS total score ≥70 and <90 and predominant positive symptoms (score of 4 or more on at least 2 core symptoms, along with a total score of at least 20 on these 4 core items plus 3 other positive symptoms), along with functional deficits (GAF ≤50). Efficacy and safety assessments were conducted at one to two-week intervals. Patients participating in the study are continuing to receive treatment with evenamide in long-term extension study 015 to determine the long-term benefits of glutamate release inhibition.

Conference call
Newron’s CEO Stefan Weber and CMO Ravi Anand will host a conference call today, June 7, at 3 pm CET/ 9 am ET.

The call can be accessed via the following dial-in numbers:
Switzerland/Europe:                  +41 (0) 58 310 5000
United Kingdom:                       +44 (0) 207 107 0613
United States:                           +1 (1) 631 570 5613

(https://www.newron.com/investors/reports-and-presentation/year/2022#reports,-presentations-&-webcasts).
 

About treatment-resistant schizophrenia
About one third of patients with schizophrenia, of which about 15% from illness onset, show virtually no beneficial response to antipsychotics (APs), despite adequate treatment. They are diagnosed as having treatment-resistant schizophrenia (TRS), operationally defined as no, or inadequate, symptomatic relief despite treatment with therapeutic doses of two antipsychotics from two different chemical classes for an adequate period. Increasing evidence supports abnormalities in glutamate neurotransmission in TRS, not targeted by current APs, along with normal dopaminergic synthesis, to explain the lack of benefit of most typical and atypical antipsychotics.

About evenamide
Evenamide has the potential to be the first add-on therapy for the treatment of patients with schizophrenia. The compound is an orally available New Chemical Entity that specifically targets voltage-gated sodium channels. Evenamide originates from Newron’s ion channel program and has a unique mechanism of action: glutamate modulation and voltage-gated sodium channel blockade. Evenamide modulates sustained repetitive firing without inducing impairment of normal neuronal excitability. It normalizes glutamate release induced by aberrant sodium channel activity. In a Phase IIa clinical study, Newron demonstrated evenamide’s evidence of efficacy in significantly improving symptoms of psychosis compared with placebo when added to two of the most commonly prescribed atypical antipsychotics in patients with chronic schizophrenia. The study also indicated that evenamide is devoid of an effect on any of the over 130 neurotransmitters, enzymes, or transporters targeted by most antipsychotics. Studies in more than 400 healthy volunteers and patients with schizophrenia have met the objective of safety on all variables.

About Newron Pharmaceuticals
Newron (SIX: NWRN, XETRA: NP5) is a biopharmaceutical company focused on the development of novel therapies for patients with diseases of the central and peripheral nervous system. The Company is headquartered in Bresso near Milan, Italy. Xadago®/safinamide has received marketing authorization for the treatment of Parkinson’s disease in the European Union, Switzerland, the UK, the USA, Australia, Canada, Latin America, Israel, the United Arab Emirates, Japan and South Korea, and is commercialized by Newron’s Partner Zambon. Supernus Pharmaceuticals holds the commercialization rights in the USA. Meiji Seika has the rights to develop and commercialize the compound in Japan and other key Asian territories. Newron is also developing evenamide as the potential first add-on therapy for the treatment of patients with symptoms of schizophrenia. For more information, please visit: www.newron.com

For more information, please contact:
Newron
Stefan Weber – CEO
+39 02 6103 46 26
pr@newron.com

UK/Europe
Simon Conway / Ciara Martin, FTI Consulting
+44 20 3727 1000
SCnewron@fticonsulting.com

Switzerland
Valentin Handschin, IRF
+41 43 244 81 54
handschin@irf-reputation.ch

Germany/Europe
Anne Hennecke, Caroline Bergmann, MC Services
+49 211 52925222
anne.hennecke@mc-services.eu

USA
Paul Sagan, LaVoieHealthScience
+1 617 374 8800, Ext. 112
psagan@lavoiehealthscience.com

Important Notices
This document contains forward-looking statements, including (without limitation) about (1) Newron’ s ability to develop and expand its business, successfully complete development of its current product candidates, the timing of commencement of various clinical trials and receipt of data and current and future collaborations for the development and commercialization of its product candidates, (2) the market for drugs to treat CNS diseases and pain conditions, (3) Newron’s financial resources, and (4) assumptions underlying any such statements. In some cases, these statements and assumptions can be identified by the fact that they use words such as “will”, “anticipate”, “estimate”, “expect”, “project”, “intend”, “plan”, “believe”, “target”, and other words and terms of similar meaning. All statements, other than historical facts, contained herein regarding Newron's strategy, goals, plans, future financial position, projected revenues and costs and prospects are forward-looking statements. By their very nature, such statements and assumptions involve inherent risks and uncertainties, both general and specific, and risks exist that predictions, forecasts, projections and other outcomes described, assumed or implied therein will not be achieved. Future events and actual results could differ materially from those set out in, contemplated by or underlying the forward-looking statements due to a number of important factors. These factors include (without limitation) (1) uncertainties in the discovery, development or marketing of products, including without limitation difficulties in enrolling clinical trials, negative results of clinical trials or research projects or unexpected side effects, (2) delay or inability in obtaining regulatory approvals or bringing products to market, (3) future market acceptance of products, (4) loss of or inability to obtain adequate protection for intellectual property rights, (5) inability to raise additional funds, (6) success of existing and entry into future collaborations and licensing agreements, (7) litigation, (8) loss of key executive or other employees, (9) adverse publicity and news coverage, and (10) competition, regulatory, legislative and judicial developments or changes in market and/or overall economic conditions. Newron may not actually achieve the plans, intentions or expectations disclosed in forward-looking statements and assumptions underlying any such statements may prove wrong. Investors should therefore not place undue reliance on them. There can be no assurance that actual results of Newron's research programs, development activities, commercialization plans, collaborations and operations will not differ materially from the expectations set out in such forward-looking statements or underlying assumptions. Newron does not undertake any obligation to publicly update or revise forward-looking statements except as may be required by applicable regulations of the SIX Swiss Exchange where the shares of Newron are listed. This document does not contain or constitute an offer or invitation to purchase or subscribe for any securities of Newron and no part of it shall form the basis of or be relied upon in connection with any contract or commitment whatsoever.